GBCS Selectis Health

Filed: 14 Jul 21, 4:22pm






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 9, 2021



(Exact Name of Registrant as Specified in its Charter)


Utah 0-15415 87-0340206

(State or other jurisdiction

of incorporation)



File Number


(I.R.S. Employer

Identification number)


8480 E. Orchard Road, Suite 4900, Greenwood Village, CO 80111

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (720) 680-0808


(Former name or former address, if changed since last report)


[  ]Written communications pursuant to Rule 425 under the Securities Act
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act


Securities registered pursuant to Section 12(b) of the Act:


Title of each Class Trading Symbol Name of each exchange on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [X]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]









The following sets forth the information required by Item 701 of Regulation S-K with respect to the unregistered sales of equity securities by Selectis Health, Inc. (the “Company”) effective July 9, 2021.


 a.On July 9, 2021, the Company sold 1,500,000 shares of Common Stock at a purchase price of $0.50 per share for a total amount of $750,000.
 b.The Common Stock was sold to nine (9) investors, each of whom qualified as an “accredited investor” within the meaning of Rule 501(a) of Regulation D under the Securities Act of 1933 as amended (the “Securities Act”).
 c.The offering was conducted through a registered broker-dealer acting as a Placement Agent. The Placement Agent was paid a cash commission of 5% of the gross proceeds of the offering proceeds, except for a 2.5% commission on the proceeds of investments by directors and officers of the Company and a 10% warrant coverage for investments from non-officer/director investors, exercisable for three years at an exercise price of $0.50 per share.
 d.The issuance of the Securities was undertaken without registration under the Securities Act in reliance upon an exemption from the registration requirements of the Securities Act set forth in Rule 506(b) of Regulation D and Section 4(2) thereunder. The investors each qualified as an “accredited investor” within the meaning of Rule 501(a) of Regulation D. In addition, the Securities, which were taken for investment purposes and not for resale, were subject to restrictions on transfer. We did not engage in any public advertising or general solicitation in connection with this transaction, and we provided the investor with disclosure of all aspects of our business, including providing the investor with our reports filed with the Securities and Exchange Commission and other financial, business and corporate information. Based on our investigation, we believed that the accredited investors obtained all information regarding the Company that each requested, received answers to all questions posed and otherwise understood the risks of accepting our Securities for investment purposes.
 e.The Warrants noted in Item 3.02(c) above are exercisable to purchase 66,500 shares of Common Stock of the Company for three years at an exercise price of $0.50 per share.
 f.The proceeds will be used for general working capital.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 Selectis Health, Inc.
Dated: July 14, 2021/s/ Lance Baller
 Lance Baller, CEO